

1 **The Effect of Ophthalmic Surgery for Graves' Orbitopathy on Quality of Life – A**
2 **Systematic Review and Meta-analysis**

3 Authors: Timothy Woo^{1*}, ChunHei Li^{1*}, Sashiananthan Ganesanathan^{1*}, Rathie Rajendram²,
4 Jimmy Uddin², Richard W.J. Lee^{2,3}, Colin Dayan⁴, Peter Taylor⁴

5 *These authors contributed equally to this work and are considered to be co-first authors

6 Affiliations

7 ¹Cardiff University School of Medicine, Cardiff, United Kingdom

8 ² Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

9 ³ Institute of Ophthalmology, Faculty of Brain Sciences, University College London, London,
10 United Kingdom

11 ⁴Thyroid Research Group, Systems Immunity Research Institute, Cardiff University School of
12 Medicine, Cardiff, United Kingdom

13

14

15 Authors:

16 Timothy Woo, timothy.woo1@nhs.net, MBBCh

17 ChunHei Li, chunhei.li@nhs.net, MBBCh

18 Sashiananthan Ganesanathan, sashiananthan.ganesanathan@nhs.net, MBBCh

19 Rathie Rajendram, r.rajendram@nhs.net, MD(RES)

20 Jimmy M Uddin, jimmy.uddin@nhs.net, FRCOphth

21 Richard Lee, richard.lee@ucl.ac.uk, MRCS, MRCOphth, PhD

22 Colin M Dayan, dayancm@cardiff.ac.uk, FRCP PhD

23 Peter N Taylor, taylorpn@cardiff.ac.uk, FRCP PhD

24

25

26

27 Running Title: Surgery on Quality of Life in Graves' Orbitopathy

28 Name and address of corresponding author: Peter Taylor, Thyroid Research Group, Systems

29 Immunity Research Institute C2 link corridor, UHW, Cardiff University School of Medicine,

30 Heath Park email: taylorpn@cardiff.ac.uk

31 telephone: + 44 (0)29 2074 8292 fax: +44 2920744671

32 Please send address for re-prints to taylorpn@cardiff.ac.uk

33

34 Key Words: Graves' Orbitopathy, Surgery, Decompression, Lid, Strabismus, GOQOL, Quality

35 of Life Systematic Review

36

37

38 **Abstract**

39 **Background**

40 Graves' orbitopathy has a profound negative impact on quality of life. Surgery is undertaken to
41 preserve vision, correct diplopia and improve aesthetics. We sought to quantify the effect of
42 different surgical approaches on quality of life.

43

44 **Methods**

45 Electronic databases Ovid–MEDLINE, EMBASE were used from inception until 22nd March,
46 2021 to identify studies assessing quality of life pre- and post-surgical intervention for Graves'
47 orbitopathy. Two reviewers independently extracted data and performed quality assessments.
48 Random-effects and Bayesian models for meta-analyses were utilised.

49

50 **Results**

51 10 articles comprising 632 patients with a mean age of 48.4 years (range 16-85 years) were
52 included. All used the Graves' Ophthalmopathy Quality of Life questionnaire (GO-QOL). For GO-
53 QOL appearance, the pooled standardised mean improvement for patients after surgery was +0.72
54 (95% CI 0.50-0.94) I^2 69% (95% CI 52-80%). For GO-QOL visual functioning, the pooled SMD
55 for patients after surgery was +0.41 (95% CI 0.25-0.58) I^2 60% (95% CI 36-74%).

56

57 For visual appearance, orbital decompression yielded the greatest improvement (SMD +0.84, 95%
58 CI 0.54-1.13) followed by eyelid surgery (SMD +0.38, 95% CI 0.05-0.70), while strabismus
59 correction had no significant effect (SMD +0.94, 95% CI -0.10-1.99). Conversely strabismus
60 correction was associated with the greatest improvement (SMD +1.25, 95% CI 0.29-2.21) in visual

61 functioning, outperforming orbital decompression (SMD +0.29, 95% CI 0.15-0.43) and eyelid
62 surgery (SMD +0.12, 95% CI -0.18-0.41).

63

64 A mean improvement in GO-QOL of greater than 10 points after orbital decompression surgery
65 was achieved in 12/14 (86%) patient-groups for appearance and 5/14 (36%) patient-groups for
66 visual functioning. A mean improvement of greater than six points was achieved in 5 of 6 (83%)
67 patient groups for strabismus surgery for both appearance and visual functioning. A mean
68 improvement of greater than six points after eyelid surgery was achieved in 2/3 (67%) patient-
69 groups and 0/3 patient-groups for appearance and visual functioning respectively.

70

71 **Conclusion**

72 Ophthalmic surgery results in substantial improvements in quality of life in patients with Graves'
73 orbitopathy, with greater perceived effects on appearance than visual function. Orbital
74 decompression has particular impact on visual appearance, strabismus surgery benefits visual
75 appearance and function equally whereas eyelid surgery benefits appearance alone.

76 **Introduction**

77

78 Graves' orbitopathy (GO), known also as Graves' ophthalmopathy or thyroid eye disease (TED),
79 is a complex autoimmune disorder and has substantial morbidity (1, 2, 3, 4). Indeed GO has been
80 shown to adversely affect quality of life, mental health, and economic activity (4, 5, 6). Its effects
81 can be profound and include double vision, orbital disfigurement and even visual loss (3).

82

83 The vast majority of patients with GO have established Graves' disease and glucocorticoids are
84 the mainstay of treatment for active disease although there is increasing use of additional agents
85 such as mycophenolate and teprotumumab (3, 7). Surgery is frequently required and is usually
86 performed during the inactive phase of disease with the goal of improving visual function and
87 cosmesis, although emergency surgery is required in the setting of sight-threatening optic nerve
88 compression (8). Options for surgical rehabilitation include orbital decompression, strabismus
89 correction, eyelid-lengthening procedures and blepharoplasty (8). While treatment is often
90 associated with objective improvements in clinical parameters, this may not necessarily translate
91 into meaningful recovery in the patient's physical, emotional and social functioning (9).

92

93 In brief, orbital decompression is the mainstay of rehabilitation for surgery as it can be utilised for
94 optic nerve compression, corneal exposure and to improve aesthetics. Common complications
95 include double vision and scarring and rarely visual loss. It requires general anaesthesia but can
96 be performed on an outpatient basis. Strabismus surgery which adjusts the extra-ocular muscles
97 requires significant expertise in thyroid eye disease, but it can be done under general or twilight
98 anaesthesia and again can be performed in an outpatient setting. A key complication is a slipped

99 muscle and movement reduction. Lid surgery is often the final step in rehabilitative surgery and is
100 used to improve lid retraction, it can be performed with twilight anaesthesia with scarring being a
101 key complication.

102

103

104 Quality of life in GO is evaluated using general health-related questionnaires and disease-specific
105 questionnaires. Disease-specific questionnaires are often less generic, permitting greater focus on
106 relevant aspects of daily life affected by the disorder, and may be more sensitive to smaller changes
107 in quality of life (9). The most widely described and validated GO-specific quality of life
108 questionnaires, at present, include the Graves' Ophthalmopathy Quality of Life (GO-QOL) and
109 the Thyroid Eye Disease Quality of Life (TED-QOL) (10). Briefly, the GO-QOL comprises two
110 domains, one pertaining to visual functioning and the other to physical appearance, each made up
111 of eight items (11). The raw score for each domain is then transformed to a total score out of 100
112 with higher scores reflecting better quality of life. The TED-QOL contains three subscales,
113 including overall quality of life, the capacity to perform daily tasks, and satisfaction of appearance
114 (12). For the GO-QOL, Terwee *et al.* proposed that a change in score of at least six points after
115 minor therapy (such as strabismus correction, eyelid-lengthening procedures and blepharoplasty)
116 or at least 10 points after major therapy (such as orbital decompression) is indicative of a minimal
117 clinically important difference (MCID) (13). **This MCID was established based upon the amount**
118 **of GO-QOL score change in patients who reported moderate subjective improvement in their**
119 **visual functioning, appearance, and overall quality of life post-procedure (13).**

120

121 The aim of this systematic review and meta-analysis was to synthesise the existing literature on
122 the impact of these different surgical interventions for the management of GO on patients' quality
123 of life, as evaluated using these disease-specific questionnaires.

124

125 **Methods**

126

127 The systematic review and meta-analysis was performed in accordance with the Preferred
128 Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. This study was
129 registered with the International Prospective Registry of Systematic Reviews (PROSPERO;
130 registration number CRD42021245615).

131

132 **Search Strategy and Study Selection**

133

134 Published articles were searched for in two major electronic databases via Ovid – MEDLINE and
135 EMBASE. Keywords for the search are listed in Supplementary Table 1. The last search was
136 performed on March 22, 2021. No restrictions were placed on the date or language of
137 publication. Only original articles were included with exclusion of abstracts, commentaries and
138 literature reviews. Articles without full text availability were also excluded. Replicates were
139 identified and removed. Studies were considered relevant if they included patients undergoing
140 rehabilitative surgery for GO, and whose quality of life was evaluated via an established disease-
141 specific questionnaire before and after surgery (GO-QOL) which there is both substantial
142 validity and reliability (Watt 2018). Articles providing primary data on pre- and post-operative
143 questionnaire scores (mean and standard deviation) were eligible for quantitative synthesis. All

144 papers yielded from the initial search were screened via title and abstract by two independent
145 reviewers (CHL, TW) to determine relevance. Thereafter, articles were read in full and selected
146 if they met the eligibility criteria by two reviewers independently. Any disagreement was
147 resolved by discussion or recourse to a third reviewer (SG). The reference lists of eligible studies
148 and review articles were also screened for additional relevant papers.

149

150 **Data Extraction**

151 Certain studies described more than one indication or surgical approach (either variations of the
152 same procedure or different operations altogether) and GO-QOL scores have been reported
153 according to these characteristics. These have therefore been summarised as individual patient
154 groups (Table 1).

155

156 Relevant information from eligible studies were retrieved in accordance with a pre-specified
157 protocol by two independent reviewers (TW, SG). These included the study's first author,
158 publication year, country of origin, study design, sample size, inclusion and exclusion criteria,
159 type of rehabilitative surgery performed, follow-up duration, disease-specific quality of life
160 questionnaire used, pre- and post-operative quality of life questionnaire scores (or their
161 differences), and post-operative complications. For the meta-analysis, the means and standard
162 deviations for pre- and post-operative GO-QOL scores were extracted.

163

164 **Quality Assessment**

165

166 Eligible studies were assessed using the National Heart, Lung, and Blood Institute (NIH) Quality
167 Assessment Tools for Before-After (Pre-Post) Studies with No Control Group and Controlled
168 Intervention Studies by two independent reviewers (TW, CHL) (14). The overall quality of each
169 study was rated as “good”, “fair”, or “poor”. The final quality rating was determined upon
170 agreement by both reviewers.

171

172 **Statistical Analysis**

173

174 Data analysis was performed using the R software with the “meta” package by two analysts
175 (CHL, SG) (15). A conventional meta-analysis was mainly employed in this study.

176 Subsequently, a Bayesian meta-analysis was performed to reaffirm the findings of the
177 conventional meta-analysis. The “brms” package was used to fit Bayesian regression models
178 (Burkner 2017). We utilised a random effects model and weakly informative prior distributions
179 to inform the study effect size (mean of 0, variance of 1 was set) and between study
180 heterogeneity variance (where the half Cauchy distribution with scaling factor of 0.5) was used
181 (Williams 2018). Bayesian methods produce credible intervals and a 95% credible interval for an
182 effect size is that region in which we believe the effect size to lie with probability 95%. This
183 cannot be done with the classical meta-analysis. Bayesian approach is also particularly
184 advantageous for random-effects analysis of among study variation where numbers of studies are
185 small such as 10 studies or less (Turner 2012).

186

187 Standardised mean differences (SMD) in GO-QOL scores pre-operatively and post-operatively
188 were calculated by Hedges’ g. Standardised mean differences were utilised due to the

189 heterogeneity of studies and also due to the relative difference in changes for the visual
190 appearance and visual functioning domains from their baseline.

191
192 The random effects model was used to pool effect sizes and mean differences in GO-QOL
193 scores. Restricted maximum likelihood was used to derive the estimator for heterogeneity τ^2 .
194 Subgroup analysis was performed to determine the effects of different types of surgery and
195 follow-up durations on the outcome. Standard error of difference between subgroup effect sizes
196 was also calculated and compared (16). Meta-regression was used to predict the effect of pre-
197 operative GO-QOL appearance and visual function scores with the individual-study effect sizes
198 generated from ophthalmic surgery. These are shown as bubble plots where individual bubbles
199 represent individual study weightage.

200
201 A funnel plot and Egger test were used to detect potential publication bias augmented by the
202 Duval and Tweedie trim-and-fill procedure which suppresses the most extreme results
203 (**Supplementary Figures 1 and 2**). Results were considered statistically significant if the p
204 value was <0.05 .

205

206 **Results**

207

208 **Study Characteristics**

209

210 The search yielded a total of 158 articles across the databases (**Figure 1**). After removal of
211 replicates, 95 articles were screened from which 32 were deemed relevant to the study. These

212 were examined fully and 10 were selected for meta-analysis after meeting the eligibility criteria.
213 For included papers no author contact was required for clarification of the data or study criteria,
214 or availability of full text.

215

216 The 10 articles comprised 632 patients with a mean age of 48.4 years ranging between 16 and 85
217 years. The majority of patients were female (74.9%). The studies encompassed the three main
218 categories of surgery - orbital decompression (n=410), strabismus correction (n=148), and eyelid
219 procedures (n=47). Amongst the 10 studies, there were 23 different groups of patients. In
220 general, patients were eligible for rehabilitative surgery if they were euthyroid with stable
221 clinical activity scores typically for at least three months. All studies were prospective or
222 retrospective observational studies with the exception of one randomised controlled trial (Sellari-
223 Franceschini *et al.*), and all employed the GO-QOL questionnaire to evaluate disease-specific
224 quality of life although one (Fayers *et al.*) also reported using the TED-QOL (20, 24). The post-
225 operative follow-up duration ranged from two months up to at least 37.9 months with a median
226 of 4 months.

227

228 Post-operative complications were sporadically reported, and all pertained to adverse effects of
229 orbital decompression, the most common being induction of diplopia (19, 21, 24). Other
230 described complications (which varied depending on the precise surgical approach) included
231 eyelid oedema and chemosis, maxillary sinus obstruction, hypoaesthesia of trigeminal nerve
232 branches, and cosmetic dissatisfaction. Cerebrospinal fluid leak was a rare complication.”

233

234

235 **Orbital Decompression**

236

237 Orbital decompression was evaluated in seven studies encompassing 14 patient groups. The most
238 common indication for orbital decompression was correction of disfiguring proptosis. Less
239 frequently decompression was performed for compressive optic neuropathy, chronic conjunctival
240 congestion, exposure keratopathy, and relief of retrobulbar sensation. A range of surgical
241 methods were reported, varying by number and location of orbital walls removed with or without
242 concomitant removal of adipose tissue, encompassing both open and endoscopic approaches.
243 Cheng *et al.* also reported a technique consisting solely of fat decompression with preservation
244 of orbital walls (18). The change in mean GO-QOL scores following orbital decompression
245 ranged between 1.8 and 40.3 for the appearance domain (median=19.6, interquartile range
246 [IQR]=14.9-23.5), and -1.7 and 34.6 for the visual function domain (median=8.0, IQR=2.5-13.2).
247 A mean improvement of greater than 10 points (i.e. greater than the MCID for major intervention
248 as proposed by Terwee *et al.*) after orbital decompression surgery was achieved in 12 of 14
249 (86%) patient groups and 5 of 14 (36%) patient groups for appearance and visual functioning
250 domains respectively (13).

251

252 **Strabismus Correction**

253

254 Four studies involving six patient groups reported on the use of strabismus correction, most
255 commonly performed for improvement of constant diplopia. The change in mean GO-QOL
256 scores after strabismus correction ranged between 2.6 and 88.2 for the appearance domain
257 (median=13.1, IQR=9.8-18.8), and 2.8 and 89.1 for the visual functioning domain (median=24.2,

258 IQR=19.3-29.1). A mean improvement of greater than six points (i.e. greater than the MCID for
259 minor intervention) after surgery was achieved in 5 of 6 (83%) of strabismus correction patient
260 groups for both appearance and visual functioning domains.

261

262 **Eyelid Procedures**

263

264 Eyelid procedures including eyelid lengthening and blepharoplasty, performed for cosmetic
265 indications such as eyelid retraction, were reported in two involving three patient groups. Mean
266 GO-QOL scores changed between 4.2 and 18.4 for the appearance domain (median=10.2,
267 IQR=7.2-14.3), and 0.2 and 4.4 for the visual functioning domain (median=3.7, IQR=2.0-4.1). A
268 mean improvement of greater than six points after eyelid surgery was achieved in 2 of 3 (67%)
269 patient groups and none (0 of 3) patient groups for appearance and visual functioning domains
270 respectively.

271

272 **Quality Assessment**

273

274 The overall quality of studies were rated by two independent reviewers (TW, CHL) based on the
275 NIH Quality Assessment Tools for the corresponding study designs (**Table 1, Supplementary**
276 **Table 2**). Of the 10 studies 1 study was felt to be of poor quality, 5 of fair quality and 4 of good
277 quality (**Supplementary Table 2**)

278

279 There was some weak evidence of publication bias. Publication bias was assessed using a funnel
280 plot, which did not show significant asymmetry for GO-QOL appearance score (p=0.126) but

281 demonstrated significant asymmetry for GO-QOL function ($p=0.0493$). However, upon
282 application of the Duval and Tweedie trim-and-fill procedure, which removed the effect size from
283 Sarici *et al.*, the p-value achieved non-significance ($p=0.661$ and 0.564 with SMD of 0.684 and
284 0.392 respectively) (23).

285

286 **Meta-analysis of the Effect of Surgery on Quality of Life**

287

288 Patients who had undergone surgery experienced significant improvements ($p<0.05$) in both
289 appearance and function domains compared to their baseline pre-operatively (**Figures 2 and 3**).
290 For the improvement in GO-QOL appearance, the pooled SMD for patients after surgery using
291 conventional (frequentist) meta-analysis was 0.72 (95% CI $0.50-0.94$) and the I^2 was 69% (95%
292 CI 52-80%) (**Figure 2**). For the improvement in GO-QOL visual functioning, the pooled SMD
293 for patients after surgery was 0.41 (95% CI $0.25-0.58$) and the I^2 was 60% (95% CI 36-74%)
294 (**Figure 3**). A Bayesian random-effects meta-analysis was also performed (**Supplementary**
295 **Figures 3 and 4**) which demonstrated a more conservative but significant improvement in GO-
296 QOL scores for both domains. Using the study-level mean GO-QOL change (a change of 10
297 points or more for all types of surgery was considered a clinically meaningful difference), the
298 odds of a clinically meaningful difference was 3.6 (95% CI $1.34-9.70$) for GO-QOL appearance
299 score and 0.769 (95% CI $0.34-1.75$) for visual functioning score.

300

301 **The Effect of Different Types of Surgery on Quality of Life**

302

303 Subgroup analysis based on type of surgery indicated a trend towards a difference on the
304 improvement in the GO-QOL scores for both appearance (Q=4.62, p=0.1) and visual functioning
305 domains (Q=5.12, p=0.08) (**Figures 4 and 5**). Eyelid surgery (SMD 0.12, 95% CI -0.18-0.41)
306 had the smallest effect on improving visual function followed by orbital decompression (SMD
307 0.29, 95% CI 0.15-0.43). Strabismus correction had the greatest effect on improving visual
308 functioning (SMD 1.25, 95% CI 0.29-2.21) and significantly outperformed eyelid surgery and
309 orbital decompression. By contrast, orbital decompression (SMD 0.84, 95% CI 0.54-1.13)
310 yielded the greatest improvement in appearance, with a lesser effect from eyelid surgery (SMD
311 0.38, 95% CI 0.05-0.70). Strabismus correction had no significant effect on improving
312 appearance (SMD 0.94, 95% CI -0.10-1.99).

313

314 **The Effect of Different Follow-up Durations on Quality of Life Post-surgery**

315

316 Most studies reported a follow-up duration of within 6 months post-operatively for the
317 completion of the GO-QOL. Two studies had a long duration of follow-up beyond 6 months,
318 with a mean of 37.9 months and 32.7 months respectively (**Table 1**). In one study there was no
319 information on the duration of follow-up (18, 20, 23).

320

321 The different duration of follow-up among the studies (up to 6 months versus more than 6
322 months versus no information) did not significantly impact on the overall changes in the GO-
323 QOL scores for both appearance (Q=1.14, p=0.57) and visual functioning (Q=0.92, p=0.63). The
324 improvement in GO-QOL scores for both appearance (SMD 0.70, 95% CI 0.44-0.96) and visual
325 function (SMD 0.39, 95% CI 0.22-0.57) remained significant after Cheng et al., Sarici et al.

326 (both more than 6 months follow-up) and Fayers et al. (no information on follow-up) were
327 excluded from the analysis (Supplementary Figures 5 and 6) (18, 20, 23).

328

329 **Relationship between Pre-operative Quality of Life and Improvement following Surgery**

330

331 Meta-regression demonstrated a significant negative correlation ($p < 0.001$) between pre-operative
332 GO-QOL scores and the effect size. The lower the pre-operative GO-QOL score, the greater the
333 improvement for both appearance and visual function after surgery (**Supplementary Figures 7**
334 **and 8**).

335

336 **Discussion**

337

338 To our knowledge, this is the first meta-analysis quantifying the effect size of surgical
339 interventions for GO on quality of life measures. Primarily, we established there was a
340 significant effect of all forms of surgical procedures on GO-QOL appearance and visual function
341 scores using both frequentist and Bayesian approaches. For appearance, the pooled standardised
342 mean improvement for patients after surgery was 0.72 (95% CI 0.50-0.94) and for visual
343 functioning, the pooled SMD for patients after surgery was 0.41 (95% CI 0.25-0.58). Using the
344 study-level mean GO-QOL change, the odds of a clinically meaningful difference was 3.6 (95%
345 CI 1.34-9.70) for GO-QOL appearance score and 0.769 (95% CI 0.34-1.75) for GO-QOL visual
346 functioning score.

347

348 The effect of surgery is important to quantify as although it is well established that clinical
349 parameters such as total eye score, diplopia and ophthalmopathy index do improve with time
350 and following surgery, these metrics may not necessarily correlate well with patients' physical
351 and psychosocial wellbeing (3, 9, 26). The value of evaluating quality of life as part of routine
352 clinical assessment of patients is therefore increasingly advocated to guide their management in a
353 holistic manner (9). Our meta-regression also indicated that patients with lower quality of life at
354 baseline were more likely to repeat more substantial improvements following surgery
355 (Supplementary Figures 7 and 8). Furthermore, it is important to indicate where the most
356 substantial improvements may be found with regard to both appearance and function. **It would**
357 **therefore be of interest to delineate whether visual function improves to a greater extent when**
358 **orbital decompression is performed for optic neuropathy rather than proptosis. There was**
359 **insufficient data to demonstrate this as GO-QOL scores for this indication was quoted in only ten**
360 **patients in one study (13).** The development and validation of disease-specific quality of life
361 measures including the GO-QOL to evaluate these aspects have allowed interventional studies to
362 define improvement from a more patient-centred point of view. Hence, quantitative synthesis of
363 the effects of surgery on these end-points provides important information to guide clinical
364 decisions while balancing the overall risks of surgical treatment.

365
366 Subgroup analysis showed that orbital decompression was associated with the greatest
367 improvement in appearance, with a standardised mean improvement of **0.84 (95% CI 0.54-1.13).**
368 This dramatic effect on visual appearance is not surprising given orbital decompression is the
369 mainstay of rehabilitative surgery and also provides substantial benefits to visual function.

393 A major strength of this study was the concomitant use of a Bayesian meta-analysis to affirm the
394 findings of the conventional meta-analysis. Bayesian analysis allowed us to integrate prior
395 knowledge and assumptions when calculating meta-analysis and despite producing a more
396 conservative effect size compared to frequentist approaches, the effect size remained
397 considerable. An additional advantage in this study is the use of the GO-QOL itself, which was
398 adopted relatively early in studies of GO and this enabled a smoother meta-analyses and clear
399 conclusions. Indeed, this meta-analysis also provides further evidence of the validity and utility
400 of the GO-QOL as the surgical procedures had the expected effects on GO-QOL with regard to
401 their relative impact on visual appearance and functioning. We observed that orbital
402 decompression influenced both appearance and function with a greater effect on appearance,
403 strabismus surgery also had benefits on appearance and functioning but to a lesser degree
404 whereas lid surgery had an impact on appearance but not visual function.

405
406 Nonetheless, there were several limitations in this study. As the GO-QOL scores extracted were
407 averages of the cohort undergoing a given procedure, we were unable to comment on the effect
408 sizes on an individual patient level and whether individual patients had attained a clinically
409 meaningful improvement (hence study-level data SMD and odds were analysed). Moreover, this
410 analysis was not based on controlled trials aside from one study (Sellari-Franceschini *et al.*),
411 which was a randomised controlled trial and therefore effects observed may have benefited from
412 a placebo effect or improvement in quality of life over time. Our studies utilised were often
413 retrospective in nature and thus prone to selection, information and publication biases. In
414 particular, Sarici *et al.*'s study reported a very small sample size with a large effect size (23). The
415 strikingly low pre-operative GO-QOL scores amongst their cohort limits the generalisability of
416 this study. We also did not incorporate unpublished conference papers or audits which may have

417 resulted in bias against studies with unremarkable findings. We were limited in our ability to
418 access two potentially eligible studies by the scope of our institutional search engine and a lack
419 of author response when contacted. Finally, certain translations of the GO-QOL, originally
420 published in Dutch and English, had yet to be formally validated *a priori* in their respective
421 populations.

422
423 To confirm the efficacy of surgery, future studies should involve comparisons with a matched
424 control population which may be challenging to conduct. With the emergence of promising novel
425 therapies such as teprotumumab it would also be interesting to evaluate how surgery performs
426 against the latest medical interventions. Additionally, GO patients often require more than one
427 operation as part of a wider rehabilitative plan, and therefore it would be of value to assess
428 whether quality of life continues to improve and to what extent. Future studies using individual
429 patient level data could be undertaken to determine the likelihood of individual patients
430 achieving a clinically meaningful improvement, and to identify predictive factors that correlate
431 with responsiveness to surgery in the context of quality of life. In turn these could assist in
432 guiding clinical decision-making and informing the likelihood of improvement amongst surgical
433 candidates.

434

435 **Conclusion**

436

437 Graves' orbitopathy can be highly debilitating with substantial long-term negative connotations
438 for patients' psychosocial wellbeing and quality of life. A multidisciplinary approach is often
439 required to manage this condition. Rehabilitative surgery can substantially improve disease-

440 specific quality of life in these patients although the choice of operation impacts on different
441 aspects of quality of life to a varying extent.

442 **Authors' Contributions**

443

444 Conceptualisation, C.M.D.; study search and selection, C.H.L., T.W.; data extraction, S.G.,
445 T.W.; data analysis, C.H.L., S.G., T.W.; manuscript preparation, C.H.L., S.G., T.W.; manuscript
446 review and editing, C.H.L., S.G., T.W., R.R., J.U., R.W.J.L., C.M.D., P.N.T.; supervision,
447 C.M.D., P.N.T.

448

449 **Author Disclosure Statement**

450

451 The authors declare no conflict of interest.

452

453 **Funding Information**

454

455 This research received no direct funding. R.W.J.L receives salary support from the NIHR
456 Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL
457 Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily
458 those of the NIHR or the Department of Health and Social Care.

459

460

461

462

463

464 **Table Heading**

465

466 Table 1. Characteristics of studies.

467

468

469

470

471 **References**

472

- 473 1. Smith TJ, Hegedüs L. Graves' Disease. *N Engl J Med*. 2016 Oct 20;375(16):1552–65.
- 474 2. Bahn RS. Graves' ophthalmopathy. *N Engl J Med*. 2010 Feb 25;362(8):726–38.
- 475 3. Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. New insights into the
476 pathogenesis and nonsurgical management of Graves orbitopathy. *Nat Rev Endocrinol*.
477 2020 Feb;16(2):104–16.
- 478 4. Ponto KA, Hommel G, Pitz S, Elflein H, Pfeiffer N, Kahaly GJ. Quality of life in a german
479 graves orbitopathy population. *Am J Ophthalmol*. 2011 Sep;152(3):483-490.e1.
- 480 5. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves'
481 orbitopathy. *Clin Endocrinol (Oxf)*. 2005 Oct;63(4):395–402.
- 482 6. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance
483 of Graves' orbitopathy. *J Clin Endocrinol Metab*. 2013 Jan;98(1):145–52.
- 484 7. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global
485 epidemiology of hyperthyroidism and hypothyroidism. *Nat Rev Endocrinol*. 2018
486 May;14(5):301–16.
- 487 8. Eckstein A, Schittkowski M, Esser J. Surgical treatment of Graves' ophthalmopathy. *Best*
488 *Pract Res Clin Endocrinol Metab*. 2012 Jun;26(3):339–58.
- 489 9. Wiersinga WM. Quality of life in Graves' ophthalmopathy. *Best Pract Res Clin Endocrinol*
490 *Metab*. 2012 Jun;26(3):359–70.

- 491 10. Lee THB, Sundar G. Quality of Life in Thyroid Eye Disease: A Systematic Review.
492 Ophthal Plast Reconstr Surg. 2020 Apr;36(2):118–26.
- 493 11. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a
494 disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the
495 GO-QOL. Br J Ophthalmol. 1998 Jul;82(7):773–9.
- 496 12. Fayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new three-item
497 questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol. 2011
498 Dec;95(12):1670–4.
- 499 13. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al.
500 Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of
501 life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001
502 Mar;54(3):391–8.
- 503 14. Study Quality Assessment Tools | NHLBI, NIH [Internet]. [cited 2021 Jul 16]. Available
504 from: <https://www.nlm.nih.gov/health-topics/study-quality-assessment-tools>
- 505 15. R: The R Project for Statistical Computing [Internet]. [cited 2020 May 15]. Available from:
506 <https://www.r-project.org/>
- 507 16. Borenstein M, Higgins JPT. Meta-analysis and subgroups. Prev Sci Off J Soc Prev Res.
508 2013 Apr;14(2):134–43.

- 509 17. Campi I, Currò N, Vannucchi G, Covelli D, Simonetta S, Fugazzola L, et al. Quantification
510 of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle
511 Ductions. *Thyroid Off J Am Thyroid Assoc.* 2021 Feb;31(2):280–7.
- 512 18. Cheng AM, Wei Y-H, Tighe S, Sheha H, Liao S-L. Long-term outcomes of orbital fat
513 decompression in Graves' orbitopathy. *Br J Ophthalmol.* 2018 Jan;102(1):69–73.
- 514 19. European Group on Graves' Orbitopathy (EUGOGO), Mourits MP, Bijl H, Altea MA,
515 Baldeschi L, Boboridis K, et al. Outcome of orbital decompression for disfiguring proptosis
516 in patients with Graves' orbitopathy using various surgical procedures. *Br J Ophthalmol.*
517 2009 Nov;93(11):1518–23.
- 518 20. Fayers T, Fayers PM, Dolman PJ. Sensitivity and responsiveness of the patient-reported
519 TED-QOL to rehabilitative surgery in thyroid eye disease. *Orbit Amst Neth.* 2016
520 Dec;35(6):328–34.
- 521 21. Fichter N, Krentz H, Guthoff RF. Functional and esthetic outcome after bony lateral wall
522 decompression with orbital rim removal and additional fat resection in graves' orbitopathy
523 with regard to the configuration of the lateral canthal region. *Orbit Amst Neth.* 2013
524 Aug;32(4):239–46.
- 525 22. Jellema HM, Merckel-Timmer E, Kloos R, Saeed P, Mourits MP. Quality of life improves
526 after strabismus surgery in patients with Graves' orbitopathy. *Eur J Endocrinol.* 2014
527 May;170(5):785–9.

- 528 23. Sarici AM, Mergen B, Oguz V, Dogan C. Intraoperative relaxed muscle positioning
529 technique results in a tertiary Center for Thyroid Orbitopathy Related Strabismus. BMC
530 Ophthalmol. 2018 Nov 23;18(1):305.
- 531 24. Sellari-Franceschini S, Rocchi R, Marinò M, Bajraktari A, Mazzi B, Fiacchini G, et al.
532 Rehabilitative orbital decompression for Graves' orbitopathy: results of a randomized
533 clinical trial. J Endocrinol Invest. 2018 Sep;41(9):1037–42.
- 534 25. Wickwar S, McBain H, Ezra DG, Hirani SP, Rose GE, Newman SP. The Psychosocial and
535 Clinical Outcomes of Orbital Decompression Surgery for Thyroid Eye Disease and
536 Predictors of Change in Quality of Life. Ophthalmology. 2015 Dec;122(12):2568-2576.e1.
- 537 26. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A
538 conceptual model of patient outcomes. JAMA. 1995 Jan 4;273(1):59–65.
- 539 27. Molzahn AE, Kalfoss M, Schick Makaroff K, Skevington SM. Comparing the importance
540 of different aspects of quality of life to older adults across diverse cultures. Age Ageing.
541 2011 Mar;40(2):192–9.
- 542
- 543
- 544
- 545 Watt, T. (2018). Measuring impact of benign thyroid diseases on quality of life, Elsevier.
546